Effect of Xinyue capsules on patients with coronary heart disease after percutaneous coronary intervention: study protocol for a randomized controlled trial

BACKGROUND: The risk of cardiovascular events remains high in patients with coronary heart disease (CHD) after successful percutaneous coronary intervention (PCI). Panax quinquefolius saponin, a major component of Xinyue capsule, has been used to treat patients with CHD. The aim of this study is to...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Ming, Zi, Ming-jie, Xi, Rui-xi, Yang, Qiao-ning, Bai, Rui-na, Zhang, Yi-sheng, Wang, Yu-hua, Wang, Pei-li, Shi, Da-zhuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4991005/
https://www.ncbi.nlm.nih.gov/pubmed/27538952
http://dx.doi.org/10.1186/s13063-016-1531-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4991005/
https://www.ncbi.nlm.nih.gov/pubmed/27538952
http://dx.doi.org/10.1186/s13063-016-1531-x

Ejemplares similares